A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis

Cancer

Volumn 101, Issue 1, 2004, Pages 156-163

  Patel, Shreyaskumar R ^a   Papadopolous, Nicholas ^a   Raymond, A Kevin ^a   Donato, Michele ^a   Seong, Chu Myong ^a,b   Yasko, Alan W ^a   Lewis, Valerae O ^a   Lin, Patrick P ^a   Champlin, Richard ^a   Benjamin, Robert S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Ewha Womans University   (South Korea)

Author keywords

Cisplatin; Doxorubicin; Ifosfamide; Peripheral blood stem cell support

Indexed keywords

CISPLATIN; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE;

ADULT; ANEMIA; ANOREXIA; ARTICLE; BLADDER DISEASE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FAILURE TO THRIVE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERBILIRUBINEMIA; KAPLAN MEIER METHOD; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OSTEOSARCOMA; OTOTOXICITY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY DISTRESS; SEPSIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CISPLATIN; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; OSTEOSARCOMA; TREATMENT OUTCOME;

EID: 3042573022     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20317     Document Type: Article

References (20)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Taylor WF, Ivins JC, Unni KK, et al. Prognostic variables in osteosarcoma: a multi-institutional study. J Natl Cancer Inst. 1989;81:21-30.
3. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neo-adjuvant Co-operative Osteosarcoma Study Group protocols. J Clin Oncol. 2002;20:776-790.
4. Bacci G, Ferrari S, Delepine N, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol. 1998;16:658-663.
5. Raymond AK, Ayala AG, Carrasco CH, et al. Osteosarcoma preoperative chemotherapy: specimen management. Cancer Bull. 1990;42:318-331.
6. Robinson E, Neugut AI, Wylie P. Clinical aspects of postirradiation sarcomas. J Natl Cancer Inst. 1988;80:233-240.
7. Brady MS, Gaynor JJ, Brennan MF. Radiation-associated sarcoma of bone and soft-tissue. Arch Surg. 1992;127:1379-1385.
8. Tabone MD, Terrier P, Pacquement H, et al. Outcome of radiation-related osteosarcoma after treatment of childhood and adolescent cancer: a study of 23 cases. J Clin Oncol. 1999;17:2789-2795.
9. Patel SR, Armen T, Carrasco CH, et al. Primary chemotherapy in malignant fibrous histiocytoma of bone - updated U.T.M.D.Anderson Cancer Center Experience. In: Banzet P, Holland J, Khayat D, Weil M, editors. Cancer treatment - an update. Paris: Springer-Verlag, 1994:577-580.
10. Bacci G, Ferrari S, Bertoni F, et al. Neoadjuvant chemotherapy for osseous MFH of the extremity: results in 18 cases and comparison with 112 contemporary osteosarcoma patients treated with the same chemotherapy regimen. J Chemother. 1997;9:293-299.
11. Bramwell VHC, Steward WP, Nooij M, et al. Neoadjuvant chemotherapy with doxorubicin and cisplatin in MFH of bone: a EOI study. J Clin Oncol. 1999;17:3260-3269.
12. Benjamin RS, Chu P, Patel SR, et al. De-differentiated chondrosarcoma - a treatable disease [abstract]. Proc Am Assoc Cancer Res. 1995;36:243.
13. Mercuri M, Picci P, Campanacci M, Rulli E. De-differentiated chondrosarcoma. Skeletal Radiol. 1995;24:409-416.
14. Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neo-adjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003;21:2011-2018.
15. Raymond AK, Chawla SP, Carrasco CH, et al. Osteosarcoma chemotherapy effect: a prognostic factor. Semin Diagn Pathol. 1987;4:212-236.
16. Hawkins DS, Felgenhauer J, Park J, et al. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. Cancer. 2002;95:1354-1365.
17. Jaffe N, Raymond AK, Ayala A, et al. Effect of cumulative courses of intraarterial CDDP on primry tumor in osteosarcoma. Cancer. 1989;63:63-67.
18. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials. 1989;10:1-10.
19. Ozaki T, Flege S, Kevric M, et al. Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol. 2003;21:334-341.
20. Bacci G, Ferrari S, Tienghi A, et al. A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity. Eur J Surg Oncol. 2001;27:98-104.